FLT3 and acute myeloid leukemia: Moreover, a retrospective analysis of their team demonstrated that older and unfit adult patients with newly diagnosed FLT3 mutated AML receiving a triplet regimen (lower intensity chemotherapy + FLT3 inhibitor + venetoclax) had a significantly higher CR/CRi rate (93% vs. 70%, P = 0.02) and longer median overall survival (NR vs. 9.5 months, P < 0.01) compared with doublet (lower intensity chemotherapy + FLT3 inhibitor) regimens (65).